AI FOR DRUG

DISCOVERY

We’re changing the way scientists decode disease biology to understand the feasibility of what has yet to be discovered. And how to reach it.

The platform

Get in touch

Mapping the path to future discoveries

Disease biology is highly fragmented and complex. Using state-of-the-art image-and-text-based machine learning models, we’ve created an unbiased, evidence-based map of the underlying biology of disease across all therapeutic areas. Through a suite of AI-powered applications, scientists can uncover the feasibility of new or existing pursuits, optimize testing strategies, and identify potential risks at the project’s onset.

ASCEND

  • Accelerate pipeline success

    Reach key milestones sooner with an optimized experimental path and identification of lynchpin experiments.

  • Improve R&D productivity

    Reduce trial and error experimentation by selecting reagents, protocols, model systems, and techniques that have been proven to work in an experimental context.

  • De-risk your portfolio

    Uncover and validate potential targets and indications in a fraction of the time to focus on the most promising pursuits, while identifying safety and efficacy risks for clinical translation.

Why drug discovery needs BenchSci

90%

Investigational new drugs (INDs) that fail in clinical trials

$500M+

Spendings per big pharma, per year, on preclinical R&D

79.5%

Experiments that fail, are redundant, or are irreproducible

See how ASCEND by BenchSci can work for you

The platform

Without the platform, it would have taken me hours to find the antibody I needed, but with it, it took me a few minutes.

Industry scientist at top 20 pharma

The platform is really, really useful—we save a lot of time and energy, and it’s helpful to communicate between us.

Industry scientist at top 20 pharma

The quality of the data is the number one value-add. I can narrow the field down to 2 or 3 candidates, compared to 10 or 20.

Industry scientist at top 20 pharma

It would have been absolutely impossible to find a commercially available antibody for our experiment without the platform.

Industry scientist at top 20 pharma

Join over 50,000 scientists using ASCEND to increase their experimental success and research velocity

Get in touch